15
Views
1
CrossRef citations to date
0
Altmetric
Review

Osteoporosis therapies

&
Pages 755-766 | Published online: 25 Feb 2005
 

Abstract

A total of 1265 patent applications claiming therapeutic utility in osteoporosis and 173 products or projects in development were analysed. Distribution of patent assignees in the original file was found to be very much biased, with the top three ranking companies, Eli Lilly, SmithKline Beecham and Merck & Co., accounting for more than 20% of the qualifying items. The most popularly investigated pharmacological class within osteoporosis is bone metabolism modulation, though cell control agents are rapidly emerging in the field and are expected to be the source of much future innovation. The top-ranking companies appear to be focusing on a maximum of two or three classes, with only slight differences of emphasis. Lilly is profiled here in detail, in order to exemplify the analytical techniques applied to the data.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.